Prudential Financial Inc. Has $761,000 Stock Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Prudential Financial Inc. boosted its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 92.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 237,720 shares of the company's stock after acquiring an additional 114,500 shares during the quarter. Prudential Financial Inc. owned approximately 0.19% of Organogenesis worth $761,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of Organogenesis by 107.8% during the third quarter. JPMorgan Chase & Co. now owns 205,943 shares of the company's stock valued at $589,000 after purchasing an additional 106,823 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Organogenesis by 54.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company's stock valued at $9,443,000 after buying an additional 1,035,120 shares during the last quarter. Verition Fund Management LLC raised its position in shares of Organogenesis by 542.8% during the third quarter. Verition Fund Management LLC now owns 78,690 shares of the company's stock worth $225,000 after acquiring an additional 66,448 shares during the last quarter. Barclays PLC raised its position in shares of Organogenesis by 251.7% during the third quarter. Barclays PLC now owns 94,809 shares of the company's stock worth $271,000 after acquiring an additional 67,855 shares during the last quarter. Finally, FMR LLC lifted its stake in shares of Organogenesis by 34.2% during the third quarter. FMR LLC now owns 173,595 shares of the company's stock valued at $496,000 after acquiring an additional 44,199 shares during the period. Institutional investors and hedge funds own 49.57% of the company's stock.

Remove Ads

Insider Activity

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares of the company's stock, valued at $851,082.90. This represents a 13.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 36.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, Morgan Stanley boosted their price objective on Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th.

Organogenesis Trading Up 13.6 %

ORGO stock traded up $0.51 during midday trading on Friday, reaching $4.26. The company's stock had a trading volume of 3,996,096 shares, compared to its average volume of 1,111,635. The business's 50-day simple moving average is $4.32 and its 200-day simple moving average is $3.68. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a 52 week low of $2.17 and a 52 week high of $6.71. The stock has a market cap of $540.29 million, a PE ratio of -71.00 and a beta of 1.79.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.